Ocumension Therapeutics (FRA:5DG)

Ocumension Therapeutics Statistics

Total Valuation

FRA:5DG has a market cap or net worth of EUR 729.47 million. The enterprise value is 669.55 million.

Market Cap	729.47M
Enterprise Value	669.55M

Important Dates

The last earnings date was Friday, November 21, 2025.

Earnings Date	Nov 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	815.38M
Shares Outstanding	n/a
Shares Change (YoY)	+14.22%
Shares Change (QoQ)	+11.42%
Owned by Insiders (%)	16.43%
Owned by Institutions (%)	9.57%
Float	297.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.29
PB Ratio	1.68
P/TBV Ratio	5.29
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-22.60
EV / Sales	10.17
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-28.88

Financial Position

The company has a current ratio of 5.29, with a Debt / Equity ratio of 0.02.

Current Ratio	5.29
Quick Ratio	4.86
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.43
Interest Coverage	-241.86

Financial Efficiency

Return on equity (ROE) is -7.76% and return on invested capital (ROIC) is -5.38%.

Return on Equity (ROE)	-7.76%
Return on Assets (ROA)	-5.07%
Return on Invested Capital (ROIC)	-5.38%
Return on Capital Employed (ROCE)	-7.50%
Revenue Per Employee	127,974
Profits Per Employee	-58,667
Employee Count	489
Asset Turnover	0.16
Inventory Turnover	4.30

Taxes

In the past 12 months, FRA:5DG has paid 124,091 in taxes.

Income Tax	124,091
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +41.13% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+41.13%
50-Day Moving Average	0.89
200-Day Moving Average	0.85
Relative Strength Index (RSI)	49.75
Average Volume (20 Days)	0

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:5DG had revenue of EUR 64.63 million and -29.63 million in losses. Loss per share was -0.04.

Revenue	64.63M
Gross Profit	27.52M
Operating Income	-33.35M
Pretax Income	-29.50M
Net Income	-29.63M
EBITDA	-19.99M
EBIT	-33.35M
Loss Per Share	-0.04

Balance Sheet

The company has 68.73 million in cash and 9.89 million in debt, giving a net cash position of 58.84 million.

Cash & Cash Equivalents	68.73M
Total Debt	9.89M
Net Cash	58.84M
Net Cash Per Share	n/a
Equity (Book Value)	434.21M
Book Value Per Share	0.53
Working Capital	78.81M

Cash Flow

In the last 12 months, operating cash flow was -19.13 million and capital expenditures -4.06 million, giving a free cash flow of -23.19 million.

Operating Cash Flow	-19.13M
Capital Expenditures	-4.06M
Free Cash Flow	-23.19M
FCF Per Share	n/a

Margins

Gross margin is 42.58%, with operating and profit margins of -51.60% and -45.84%.

Gross Margin	42.58%
Operating Margin	-51.60%
Pretax Margin	-45.65%
Profit Margin	-45.84%
EBITDA Margin	-30.94%
EBIT Margin	-51.60%
FCF Margin	n/a

Dividends & Yields

FRA:5DG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.22%
Shareholder Yield	-14.22%
Earnings Yield	-4.06%
FCF Yield	-3.18%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:5DG has an Altman Z-Score of 8.45 and a Piotroski F-Score of 2.

Altman Z-Score	8.45
Piotroski F-Score	2